➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Harvard Business School
AstraZeneca
McKesson
McKinsey

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Patent: 8,828,391

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,828,391
Title:Method for EGFR directed combination treatment of non-small cell lung cancer
Abstract: The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine kinase inhibitor (TKI) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mAB is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m.sup.2 repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least monthly to a patient in need of such treatment.
Inventor(s): Denis; Louis (Wiesbaden, DE), Lorence; Robert Michael (Bethesda, MD), Shahidi; Mehdi (Sutton, GB), Solca; Flavio (Vienna, AT)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:13/471,500
Patent Claims:see list of patent claims

Details for Patent 8,828,391

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) 2031-05-17 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) 2031-05-17 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) 2031-05-17 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) 2031-05-17 RX search
Eli Lilly Co PORTRAZZA necitumumab INJECTABLE;INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL 125547 001 2015-11-24   Start Trial Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) 2031-05-17 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Moodys
Merck
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.